EA200301041A1 - STIMULATION OF OSTEOGENESIS USING HYBRID PROTEINS OF LIGAND FOR RANK - Google Patents

STIMULATION OF OSTEOGENESIS USING HYBRID PROTEINS OF LIGAND FOR RANK

Info

Publication number
EA200301041A1
EA200301041A1 EA200301041A EA200301041A EA200301041A1 EA 200301041 A1 EA200301041 A1 EA 200301041A1 EA 200301041 A EA200301041 A EA 200301041A EA 200301041 A EA200301041 A EA 200301041A EA 200301041 A1 EA200301041 A1 EA 200301041A1
Authority
EA
Eurasian Patent Office
Prior art keywords
osteoblasts
osteogenesis
rank
stimulation
ligand
Prior art date
Application number
EA200301041A
Other languages
Russian (ru)
Inventor
Джонатан Лэм
Ф. Патрик Росс
Стивен Л. Тайтельбаум
Original Assignee
Барнс-Джуиш Хоспитал
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Барнс-Джуиш Хоспитал filed Critical Барнс-Джуиш Хоспитал
Publication of EA200301041A1 publication Critical patent/EA200301041A1/en

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6863—Cytokines, i.e. immune system proteins modifying a biological response such as cell growth proliferation or differentiation, e.g. TNF, CNF, GM-CSF, lymphotoxin, MIF or their receptors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70575—NGF/TNF-superfamily, e.g. CD70, CD95L, CD153, CD154
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/42—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving phosphatase
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/48—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase
    • C12Q1/485—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving transferase involving kinase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value
    • G01N2500/10—Screening for compounds of potential therapeutic value involving cells

Abstract

Раскрыт способ стимуляции остеогенеза, включающий введение эффективного количества 1) олигомерного комплекса одного или более RANKL, гибридного белка RANKL, его аналога, производного или миметика, 2) остеогенного соединения, способного повышать активность одного или более внутриклеточных белков в остеобластах или в предшественниках остеобластов, при этом указанная активность является признаком образования кости, или 3) остеогенного соединения, способного инактивировать одну или более фосфатазу в остеобластах или в предшественниках остеобластов, при этом указанная инактивация является признаком образования кости. Этот способ может быть также использован для лечения заболевания или состояния, проявляющегося, по крайней мере частично, в потере костной массы, включающий введение пациенту фармацевтической композиции, включающей олигомерный комплекс или остеогенное соединение, описанное в настоящей заявке.Международная заявка была опубликована вместе с отчетом о международном поиске.A method of stimulating osteogenesis is disclosed, including the administration of an effective amount of 1) an oligomeric complex of one or more RANKL, RANKL hybrid protein, its analogue, derivative or mimetic, 2) an osteogenic compound capable of increasing the activity of one or more intracellular proteins in osteoblasts or in precursors of osteoblasts, this activity is a sign of bone formation, or 3) an osteogenic compound capable of inactivating one or more phosphatase in osteoblasts or in the precursors of osteoblasts astov, while this inactivation is a sign of bone formation. This method can also be used to treat a disease or condition manifested, at least in part, in bone loss, including administering to a patient a pharmaceutical composition comprising an oligomeric complex or an osteogenic compound described in this application. The international application was published along with international search.

EA200301041A 2001-03-22 2002-03-22 STIMULATION OF OSTEOGENESIS USING HYBRID PROTEINS OF LIGAND FOR RANK EA200301041A1 (en)

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
US27785501P 2001-03-22 2001-03-22
US31116301P 2001-08-09 2001-08-09
US32923101P 2001-10-12 2001-10-12
US32887601P 2001-10-12 2001-10-12
US32939301P 2001-10-15 2001-10-15
PCT/US2002/009271 WO2002080955A1 (en) 2001-03-22 2002-03-22 Stimulation of osteogenesis using rank ligand fusion proteins

Publications (1)

Publication Number Publication Date
EA200301041A1 true EA200301041A1 (en) 2004-08-26

Family

ID=27540621

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200301041A EA200301041A1 (en) 2001-03-22 2002-03-22 STIMULATION OF OSTEOGENESIS USING HYBRID PROTEINS OF LIGAND FOR RANK

Country Status (5)

Country Link
EP (1) EP1385532A4 (en)
JP (1) JP2004526748A (en)
CA (1) CA2441538A1 (en)
EA (1) EA200301041A1 (en)
WO (1) WO2002080955A1 (en)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU9303001A (en) 2000-09-22 2002-04-02 Immunex Corp Screening assays for agonists or antagonists of receptor activat or of nf-kb
DK1732575T3 (en) * 2004-02-26 2011-03-28 Osteologix As Strontium containing compounds for use in the prevention or treatment of necrotic bone diseases
EP1736482A1 (en) * 2005-06-20 2006-12-27 INSERM (Institut National de la Santé et de la Recherche Medicale) Recombinant trimeric 4-1BBL
CA2651597C (en) 2006-05-12 2013-02-05 Keio University Detection of inflammatory disease and composition for prevention or treatment of inflammatory disease
WO2008044797A1 (en) * 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Osteopenia model animal
WO2008044379A1 (en) 2006-10-11 2008-04-17 Oriental Yeast Co., Ltd. Bone loss model animal
JP5191390B2 (en) * 2006-10-11 2013-05-08 オリエンタル酵母工業株式会社 Reagent containing fusion protein of soluble RANKL and epitope tag
US8722075B2 (en) * 2008-10-24 2014-05-13 Warsaw Orthopedic, Inc. Compositions and methods for promoting bone formation
CN114391506A (en) * 2021-12-24 2022-04-26 华中科技大学同济医学院附属协和医院 Exercise method for restoring rhythm and promoting growth and development of bone tissue

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4138013B2 (en) * 1996-12-23 2008-08-20 イミュネックス・コーポレーション Ligand for receptor activator of NF-KAPPA B, a member of TNF superfamily
ES2317694T3 (en) * 1998-05-14 2009-04-16 Immunex Corporation METHOD TO INHIBIT OSTEOCLASTIC ACTIVITY.
CN1318105A (en) * 1998-09-15 2001-10-17 M&E生物技术公司 Methods for down-regulating osteoprotegerin ligand activity
US7300774B1 (en) * 1999-12-09 2007-11-27 The Regents Of The University Of California Multimeric fusion proteins of the TNF superfamily ligands

Also Published As

Publication number Publication date
WO2002080955A1 (en) 2002-10-17
EP1385532A1 (en) 2004-02-04
JP2004526748A (en) 2004-09-02
CA2441538A1 (en) 2002-10-17
EP1385532A4 (en) 2004-12-15

Similar Documents

Publication Publication Date Title
CY1120977T1 (en) TREATMENT OF GYLICOGENE STORAGE DISEASES II
DE69233559D1 (en) OSTEOGENIC PROTEINS IN THE TREATMENT OF METABOLIC BONE DISEASES
DE3851776D1 (en) Use of IGF-II for the treatment of bone diseases.
ATE399553T1 (en) PHARMACEUTICAL COMPOSITIONS CONTAINING DEXTROMETHORPHAN AND QUINIDENE FOR THE TREATMENT OF NEUROLOGICAL DISEASES
BRPI0411241A (en) therapeutic agents useful for treating pain
ATE355374T1 (en) THERAPEUTIC AGENTS AND METHODS OF THEIR USE FOR THE TREATMENT OF AMYLOIDOGENIC DISEASES
EA200501023A1 (en) THERAPEUTIC STRUCTURES FOR THE TREATMENT OF DISEASES ASSOCIATED WITH BETA AMYLOID
ATE204178T1 (en) METHOD FOR TREATING AND PREVENTING TYPE 1 DIABETIS BY ORAL ADMINISTRATION OF INSULIN
BR9813373A (en) Compound, process for preparing it, pharmaceutical composition, process for preparing it, use of a compound, and, processes for effecting immunosuppression and for treating or reducing the risk of reversibly obstructive airway disease in a patient
EA200101005A1 (en) HIGHLY EFFICIENT COMPOSITIONS CONTAINING DIHYDROERGOTAMINE
BRPI0108977B8 (en) azacyclic compounds, pharmaceutical composition and use of a compound or pharmaceutically acceptable salt thereof
DE69230112T2 (en) ADVANCED DRUG DELIVERY SYSTEM AND METHOD FOR TREATING PSYCHIATRIC, NEUROLOGICAL AND OTHER DISEASES WITH CARBAMAZEPINE
RU92016244A (en) SUGARINE DERIVATIVES-INHIBITORS OF PROTEOLYTIC ENZYMES
BR0210122A (en) Compound or a pharmaceutically acceptable salt thereof, method for treating or preventing a disease, use of the compound or salt thereof, and method for preparing the same
EP1658853A4 (en) Remedy for internal administration against cranial nerve diseases containing mesenchymal cells as the active ingredient
RU95106821A (en) Cyclopeptides, method of their synthesis, pharmaceutical composition and method of its preparing
EA200301041A1 (en) STIMULATION OF OSTEOGENESIS USING HYBRID PROTEINS OF LIGAND FOR RANK
BR0210392A (en) Compound, methods of treating a patient who has or prevent a patient from contracting a disease or condition and preparing a compound, and, using a compound
DE60233433D1 (en) PHARMACEUTICAL PREPARATION containing a catechin, ascorbic acid, proline and lysine FOR THE TREATMENT OF NEOPLASTIC DISEASES
SE0102147D0 (en) New methods
BR0211970A (en) Use of bibn4096 in combination with other anti-migraine drugs to treat migraine.
DE60009146D1 (en) PHARMACEUTICAL PREPARATIONS FOR TREATING DNA VIRAL INFECTIONS, WHICH CONTAIN A LOOP DIURETIC AND A HEART GLYCOSIDE
KR950031085A (en) Pharmaceutical composition for the treatment of epidermal proliferation disease
DE69501359D1 (en) Use of phosphate diesters for the treatment of diseases of the retina
EA200401586A1 (en) COMPOSITIONS FOR THERAPEUTIC USE, INCLUDING VITAMIN A, SALT OF METAL AND INSULIN OR GROWTH HORMONE